Modern Dental Group Limited Overview
Modern Dental Group is the world's largest listed, vertically integrated dental-laboratory network. It manufactures and distributes custom-made dental prostheses to dentists, clinics, hospitals and dental service organisations (DSOs) in more than 28 countries.
The business model has two layers:
-
A low-cost offshore production backbone of about 5,900 technicians, mainly in Dongguan (China), Thailand and Vietnam.
-
A layer of locally branded, customer-facing sales and service businesses: Permadental, Labocast, Elysee Dental, MicroDental, Modern Dental Pacific/Southern Cross, YZJ, Hexa Ceram and others.
The group is consolidating a fragmented, cottage-industry market by turning digitalisation, particularly intra-oral scanner adoption, into faster turnaround and lower unit cost. In FY2025 it delivered record revenue of HK$3.74bn, EBITDA of HK$938m and net profit of HK$601m, with net cash on its bank borrowings.
Europe is now just over half of revenue, while North America and Greater China are shrinking in share. The group remains a founding-family-controlled company with a combined chairman and CEO.
Company's own description (FY2025 results announcement and 1H2026 interim announcement). The Group describes itself as a leading global dental prosthetic device provider focused on custom-made prostheses. Its portfolio has three product lines:
-
Fixed prosthetic devices, such as crowns and bridges.
-
Removable prosthetic devices, such as dentures.
-
"Others": orthodontic devices, sports guards, anti-snoring devices, raw materials, dental equipment (including intra-oral scanners), clear aligners, and educational events and seminars.
Per Note 1 of the 1H2026 interim statements, the Group is principally engaged in the production and distribution of dental prosthetic devices and other dental appliances, including clear aligners.
Independent characterisation. MDG is a B2B contract manufacturer of patient-specific medical devices. Each unit is a "case" made to a dentist's impression or digital scan. Its economics are shaped by four features.
Revenue model: - About 94% of revenue is product revenue from custom devices, priced per case. In FY2025 it sold 2.85m cases at an average selling price (ASP) of HK$1,229, or HK$1,479 excluding Hexa Ceram.
-
The balance (HK$232.9m in FY2025) is distribution revenue from raw materials and dental equipment, notably intra-oral scanners. It also includes revenue from the proprietary TrioClear aligner and from education services.
-
All revenue is recognised "at a point in time" on delivery. There is no material subscription or licensing revenue.
Value chain position: MDG sits between dental-materials and equipment makers upstream (zirconia, alloys, scanners, CAD/CAM mills and printers) and dental practices downstream. It captures the labour-intensive design-and-finish step. Local sales and service entities own the dentist relationship, while offshore hubs do the volume production. Digital files now travel electronically (35–43% of volume is "digital solution" cases), which removes the physical-impression bottleneck and favours scaled offshore producers.
Customer types: - Independent dentists and group practices.
-
Corporate dental groups and DSOs, especially in Australia and North America.
-
Public hospitals and government-related orders in Hong Kong.
-
Universities: the group runs an in-house lab at The University of Hong Kong's dental school.
-
Distributors.
-
No single customer exceeds 10% of revenue.
End-markets: - Restorative dentistry: crowns, bridges and implant restorations.
-
Prosthodontics: full and partial dentures.
-
Orthodontics: clear aligners and appliances.
-
Dental sleep medicine: anti-snoring and obstructive sleep apnoea (OSA) appliances.
-
Sports dentistry.
Demand drivers: - Ageing populations and the shift of dentists to digital workflows.
-
The cost advantage of offshore production for reimbursement-constrained payers, e.g. German statutory insurance co-payments and Australian insurers.
-
Consolidation of small labs.
Strategy
10.1 Stated strategy: recurring themes in the FY2025 annual results and 1H2026 interim. Management restates the same themes in each document; they are paraphrased below.
-
Digitalisation as an irreversible industry trend that accelerates consolidation. Digital solution cases are about 35–43% of volume. Centralised digital workflows, scanner partnerships, proprietary solutions and education centres are described as raising entry barriers and driving margin expansion and share gains.
-
Geographic production diversification. Mass-scale sites in China, Vietnam and Thailand plus onshore labs in the US, Europe and Australia are presented as a tariff and geopolitical hedge. Management contrasts this with competitors that rely on single-country manufacturing.
-
A full "dental ecosystem" rather than a lab. Prosthetics plus aligners, scanners, sleep devices and education.
-
Selective M&A, JVs and partnerships, with priority on TrioClear aligners and distribution networks.
-
Investment in mass-scale production, AI, automation, R&D and digital innovation.
-
Margin discipline. Exit low-margin segments in China, rationalise loss-making DSO accounts in North America, and focus on mid- and high-value customers.
10.2 Strategic initiatives in the last 24 months
10.3 Medium-term targets and guidance.
-
No quantitative medium-term revenue, margin or EPS targets are publicly disclosed.
-
The company guides only through positive profit alerts:
-
FY2025 alert (16 Mar 2026): revenue HK$3.675–3.775bn; EBITDA HK$920–950m; net profit HK$590–610m. Actuals came in within the ranges.
-
FY2023 alert (11 Mar 2024): revenue HK$3.125–3.225bn; net profit HK$390–410m.
-
Payout policy: - FY2024 press materials describe the payout ratio as "raised to 40%".
-
FY2025 DPS of 25.7 cents is about 40% of EPS of 63.7 cents.
-
1H2026 DPS of 14.0 cents is about 35% of interim EPS.
Products & Services
The Group does not publish SKU-level specifications or price lists. The table below is organised by segment and brand, from filings, company releases and the brands' own trade communications. Pricing is per case and set by local brand; it is not centrally disclosed except as ASPs.
5.1 Fixed prosthetic devices (FY2025: 1,309,530 cases at an ASP of HK$1,684)
5.2 Removable prosthetic devices (FY2025: 844,068 cases at an ASP of HK$1,085)
5.3 Others
5.4 Brand architecture by region
Product Portfolio
| Offering | Description / capabilities | Target customer | Year / status | Pricing |
|---|---|---|---|---|
Metal-ceramic (PFM) crowns & bridges | Porcelain fused to a cast-metal substructure; single units and multi-unit bridges | General dentists; insurance-driven markets (Germany, France) | Legacy core line | Per unit; ASP n.d. by type |
Full-metal crowns & bridges | Cast alloy restorations | Posterior and economy segments | Legacy | Per unit |
Metal-free crowns & bridges | All-ceramic (zirconia, glass-ceramic) restorations; growing share through CAD/CAM | Aesthetic and premium practices | Expanding with digital workflows | Per unit |
Custom implant abutments & implant restorations | Patient-specific abutments and screw- or cement-retained crowns | Implant practices; DSOs | Prices in China affected by VBP from 2023 | Per unit |
Digital solution cases | Restorations designed from intra-oral scans and produced via centralised CAD/CAM. 1,039,188 cases in FY2025 (+32.7%) and 627,773 in 1H2026 (+29.2%). | Scanner-equipped clinics | 35–43% of total volume (1H2026) | — |
| Offering | Description | Target | Status |
|---|---|---|---|
Full dentures | Conventional acrylic complete dentures | Elderly and edentulous patients; public-health channels | Core |
Partial dentures (with metal framework) | Cast cobalt-chrome frameworks with acrylic teeth | General dentists | Core |
Partial dentures (without metal framework) | Flexible or acrylic partials | Economy and aesthetic segments | Core |
Digital dentures | CAD-designed, milled or printed dentures. Management cites these as the main European volume driver in FY2023–1H2026. | European practices | Launched in Europe over FY2023–2025 (exact year n.d.) |
| Offering | Description | Target | Key data |
|---|---|---|---|
TrioClear | Proprietary clear-aligner brand; Dr Chan Ronald is director and CEO of the aligner business | General dentists and orthodontists in Europe, Asia and Australia | Revenue: FY2021 21.0; FY2022 25.8; FY2023 33.7; FY2024 47.6; FY2025 59.7; 1H2026 32.8 (+20.2%) HK$m |
Digital Sleep Design appliance | Proprietary nylon oral appliance for obstructive sleep apnoea and snoring (Australia) | Dentists and sleep physicians | Acquired Feb 2025; FY2025 revenue contribution HK$21.2m since acquisition |
Orthodontic appliances | Retainers, functional and removable appliances | Orthodontists | Part of "other custom-made devices" (697,485 cases in FY2025, ASP HK$548) |
Sports guards / night guards | Custom mouthguards | Dentists, sports clubs | Within "other custom-made" |
Intra-oral scanners and dental equipment | Distribution of third-party scanners through joint ventures and distribution agreements (FY2022 disclosure). Scanner sales in Europe rose 13.6% in FY2022. | Clinics digitising their workflow | Part of "Others" (HK$140.1m in 1H2026; increase attributed to dental equipment) |
Raw materials | Resale of dental materials | Clinics and labs | Part of "Others" |
Education and events | THINK DIGITAL education symposia; World Dental Forum (Beijing, 4th edition 2017); Hexa Ceram 30th-anniversary symposium (May 2025) | Dentists | Service revenue within "Others" |
| Region | Brands |
|---|---|
Western Europe | Permadental & Semperdent (Germany/Netherlands), Labocast (France), Elysee Dental (Benelux, Scandinavia, Spain); MD3D Solutions (Emmerich, Germany, digital) |
Hong Kong / China | Modern Dental Laboratory (HK); YZJ / Yangzhijing Dental Laboratory (Shenzhen) |
North America | MicroDental Laboratories (US); Modern Dental USA; Quantum Dental Laboratory/Technologies (Canada); Essex Dental (Ontario, acquired 2026); other cited lab names include Sundance Dental and Peak Dental Solutions |
Australia / NZ | Modern Dental Pacific; Southern Cross Dental; Andent; Digital Sleep Design |
Southeast Asia / others | Hexa Ceram (Thailand); Apex Digital Dental (Malaysia); Modern Dental SG (Singapore); Modern Dental TW (Taiwan); Labo Ocean Indien (Indian Ocean) |
Financial Narrative
All figures are in HK$m, IFRS and audited, from the final results announcements for FY2021–FY2025. "Operating income" is gross profit plus other income and gains, less selling, administrative and other operating expenses, before finance costs and associates. It is analyst-derived and reconciles exactly to reported profit before tax.
6.1 Income statement
DPS composition: - FY2021: interim 7.5 + special 5.0 + final 4.4
-
FY2022: 3.7 + 4.4
-
FY2023: 6.0 + 9.0
-
FY2024: 8.0 + 9.2
-
FY2025: 10.7 + 15.0
6.2 Margins (%)
Revenue CAGR FY2021–FY2025: about 6.0% a year in HK$. In original currencies the CAGR is higher, because FY2022 included a 10.3% EUR and 6.8% AUD depreciation against HK$. Net-profit CAGR over the same period is about 13.6%.
6.3 Balance sheet (31 December, HK$m)
At 30 Jun 2026 (unaudited): - Cash HK$828.9m; bank borrowings HK$445.9m, giving net bank cash of HK$383.3m.
-
Leases HK$163.5m; total equity HK$3,540.2m; goodwill HK$1,294.0m; intangibles HK$365.9m.
-
Put-option liabilities (Hexa Ceram and Digital Sleep minorities) HK$83.7m.
-
Company gearing ratio 6%.
6.4 Cash flow (HK$m)
Capex notes: - FY2021 and FY2024 are property, plant and equipment (PP&E) additions, used as a proxy because a "capital expenditure" figure was not separately stated in the documents reviewed.
-
FY2022, FY2023 and FY2025 are the company's stated capex.
-
FY2025 acquisition outflows (Hexa Ceram HK$196.1m net; Digital Sleep HK$14.8m) are excluded from capex.
1H2026 cash flow (unaudited): OCF HK$330.2m (1H2025: 289.7); capex HK$34.5m; dividends paid HK$140.2m; buyback HK$3.7m; Essex Dental net outflow HK$15.7m.
6.5 Ratios (analyst-derived)
6.6 Trend commentary.
-
FY2021 to FY2022: COVID inflection. FY2021 was a post-COVID rebound year: revenue +34.9%, EBITDA HK$626m. FY2022 then fell sharply: net profit −38.8%, gross margin down 3.6 points to 48.9%. Management cites:
-
Under-utilised capacity from the Q1 2022 Mainland China production suspension and recurring outbreaks.
-
Euro (−10.3%) and AUD (−6.8%) depreciation against HK$.
-
A mix shift towards lower-margin scanner sales. Operating cash flow halved, also because tax paid rose by HK$54.3m.
-
-
FY2023: digital re-rating. Revenue rose 12.1% and gross margin recovered 4.7 points to 53.6%. Drivers were utilisation, a rising digital-case share (Mainland-produced digital cases +55.9% to 857k) and RMB weakness against HK$, which lowered the China-based cost base. Net profit rose 82.4%.
-
FY2024: plateau. Revenue +6.1% but net profit only +1.2%. Costs absorbed HK$15.5m of acquisition costs, HK$14.2m of relocation costs and HK$26.2m of FX losses, while finance costs peaked at HK$51.7m on higher HIBOR. Adjusted EBITDA still grew 6.9%.
-
FY2025: step-change. Revenue +11.1%, gross margin +2.3 points to 55.8%, EBITDA +32.4%, net profit +47.7%. Management cites three causes:
-
Efficiency from digital cases.
-
EUR appreciation against RMB and HK$ from April 2025. This is a structural natural hedge: euro revenue against a renminbi cost base.
-
Geographic mix: higher-margin Europe and Australia grew 15.5%, while lower-margin US and Greater China each fell about 7%. Hexa Ceram added HK$215.8m of revenue and HK$24.8m of profit but dilutes gross margin. FX turned from a HK$26.2m loss to a HK$23.5m gain, and other operating expenses fell 68.8%.
-
-
1H2026: margin expansion without FX help. Gross margin was 58.1% and the net margin 18.6%. Other operating expenses now include an FX loss of HK$14.1m, so the improvement is operational. Finance costs nearly halved to HK$11.6m. The group became net cash on bank debt from FY2023, and by mid-2026 its net cash was HK$383m.
-
Watch item: working capital. Trade receivables rose to HK$821.8m at 30 Jun 2026 from HK$698.6m at end-2025. Receivables aged more than three months reached HK$256.4m (31% of the total). The cash conversion cycle has drifted up from 81.5 to 94.5 days over five years.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Representative products |
|---|---|---|
Fixed prosthetic devices | Restorative devices: crowns, bridges and implant restorations | Metal-ceramic, full-metal and metal-free (e.g. zirconia) crowns and bridges; custom implant abutments; implant-borne restorations |
Removable prosthetic devices | Full and partial dentures, with or without metal frameworks | Conventional and digital (milled/printed) dentures; cast-metal partials |
Others | Orthodontic devices, sports guards, anti-snoring devices, raw materials, dental equipment (including intra-oral scanners), clear aligners, education services | TrioClear aligners; Digital Sleep nylon OSA appliance; scanner distribution; THINK DIGITAL symposia |
Revenue by Segment
| Segment | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Fixed prosthetic devices revenue (HKD Mn) | 1,936.0 | 1,803.5 | 1,985.0 | 2,048.6 | 2,205.3 |
Removable prosthetic devices revenue (HKD Mn) | 537.4 | 535.1 | 713.0 | 799.0 | 916.0 |
Others revenue (HKD Mn) | 481.8 | 491.5 | 474.0 | 516.4 | 615.2 |
Total revenue (HKD Mn) | 2,955.2 | 2,830.1 | 3,172.0 | 3,364.0 | 3,736.5 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment and Segment Margins & Growth (%)
| Segment | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Fixed gross profit (HKD Mn) | 1,053.5 | 922.5 | 1,093.0 | 1,129.6 | 1,282.1 |
Removable gross profit (HKD Mn) | 293.6 | 268.9 | 387.1 | 438.3 | 495.7 |
Others gross profit (HKD Mn) | 203.6 | 191.9 | 220.6 | 231.0 | 307.2 |
Fixed gross margin (%) | 54.4 | 51.2 | 55.1 | 55.1 | 58.1 |
Removable gross margin (%) | 54.6 | 50.3 | 54.3 | 54.9 | 54.1 |
Others gross margin (%) | 42.3 | 39.0 | 46.5 | 44.7 | 49.9 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Segment | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Fixed YoY growth (%) | 10.1 | 3.2 | 7.6 |
Removable YoY growth (%) | 33.2 | 12.1 | 14.6 |
Others YoY growth (%) | -3.6 | 8.9 | 19.1 |
Fixed share of revenue (%) | 62.6 | 60.9 | 59.0 |
Removable share of revenue (%) | 22.5 | 23.8 | 24.5 |
Others share of revenue (%) | 14.9 | 15.4 | 16.5 |
Revenue by Segment (1H2025 revenue–1H2026 revenue)
| Segment (HKD Mn unless stated) | 1H2025 revenue | 1H2026 revenue | 1H2026 gross profit | 1H2026 gross margin (%) |
|---|---|---|---|---|
Fixed | 1,098.3 | 1,184.7 | 721.9 | 61.0 |
Removable | 447.4 | 492.9 | 276.5 | 56.1 |
Others | 289.1 | 354.9 | 182.4 | 51.4 |
Total | 1,834.8 | 2,032.5 | 1,180.9 | 58.1 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (HKD Mn) | 2,955.2 | 2,830.1 | 3,172.0 | 3,364.0 | 3,736.5 |
Revenue growth (%) | 34.9 | -4.2 | 12.1 | 6.1 | 11.1 |
Gross profit (HKD Mn) | 1,550.7 | 1,383.3 | 1,700.7 | 1,798.9 | 2,085.0 |
Selling & distribution expenses (HKD Mn) | 359.5 | 375.0 | 414.1 | 456.2 | 482.5 |
Administrative expenses (HKD Mn) | 697.3 | 702.2 | 747.9 | 762.1 | 852.8 |
Operating income (HKD Mn, derived) | 486.6 | 316.0 | 551.1 | 579.9 | 793.9 |
EBITDA (HKD Mn, company-defined) | 626.4 | 463.4 | 694.5 | 708.8 | 938.1 |
Adjusted EBITDA (HKD Mn, non-IFRS) | 628.7 | 464.8 | 693.9 | 741.5 | 941.8 |
Depreciation & amortisation (HKD Mn) | 140.4 | 148.1 | 145.5 | 139.2 | 149.1 |
Finance costs (HKD Mn) | 23.1 | 26.3 | 41.2 | 51.7 | 34.4 |
Profit before tax (HKD Mn) | 464.1 | 290.1 | 509.6 | 527.1 | 759.5 |
Income tax (HKD Mn) | 103.7 | 69.6 | 107.4 | 120.2 | 158.3 |
Net profit (HKD Mn) | 360.4 | 220.5 | 402.2 | 406.9 | 601.2 |
Profit attributable to owners (HKD Mn) | 360.8 | 220.5 | 404.1 | 408.0 | 597.0 |
Basic EPS (HK cents) | 37.7 | 23.1 | 42.4 | 43.2 | 63.7 |
Diluted EPS (HK cents) | 37.7 | 23.1 | 42.4 | 43.2 | 63.7 |
Dividend per share (HK cents) | 16.9 | 8.1 | 15.0 | 17.2 | 25.7 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 52.5 | 48.9 | 53.6 | 53.5 | 55.8 |
Operating margin (%, derived) | 16.5 | 11.2 | 17.4 | 17.2 | 21.2 |
EBITDA margin (%) | 21.2 | 16.4 | 21.9 | 21.1 | 25.1 |
Net margin (%) | 12.2 | 7.8 | 12.7 | 12.1 | 16.1 |
Effective tax rate (%, derived) | 22.3 | 24.0 | 21.1 | 22.8 | 20.8 |
Balance Sheet and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (HKD Mn) | 3,657.4 | 3,539.1 | 3,952.8 | 4,074.9 | 4,540.3 |
Cash & cash equivalents (HKD Mn) | 633.2 | 444.4 | 697.7 | 816.8 | 767.0 |
Bank borrowings: current (HKD Mn) | 173.4 | 84.9 | 63.7 | 115.9 | 70.9 |
Bank borrowings: non-current (HKD Mn) | 499.7 | 545.3 | 612.5 | 621.2 | 407.4 |
Total bank borrowings (HKD Mn) | 673.1 | 630.2 | 676.2 | 737.2 | 478.2 |
Lease liabilities (HKD Mn) | 160.0 | 158.0 | 176.0 | 187.1 | 175.9 |
Net bank debt (HKD Mn; negative = net cash) | 35.1 | 182.5 | -21.7 | -79.9 | -289.0 |
Net debt incl. leases (HKD Mn) | 195.1 | 340.5 | 154.3 | 107.2 | -113.1 |
Total equity (HKD Mn) | 2,358.7 | 2,333.5 | 2,643.1 | 2,725.6 | 3,295.6 |
Equity attributable to owners (HKD Mn) | 2,348.4 | 2,320.0 | 2,632.3 | 2,715.9 | 3,288.8 |
Goodwill (HKD Mn) | 1,185.7 | 1,132.4 | 1,159.6 | 1,098.9 | 1,286.7 |
Intangible assets (HKD Mn) | 255.2 | 228.2 | 214.6 | 200.4 | 362.9 |
Goodwill + intangibles as % of total assets (%) | 39.4 | 38.4 | 34.8 | 31.9 | 36.3 |
Net current assets / working capital (HKD Mn) | 727.1 | 736.4 | 1,016.4 | 1,170.3 | 1,252.9 |
Company gearing ratio (%, company definition) | 18 | 22 | 16 | 14 | 10 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansCash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (HKD Mn) | 525.1 | 258.3 | 575.8 | 521.2 | 763.1 |
Capital expenditure (HKD Mn) | 135.2 | 185.4 | 159.7 | 139.8 | 72.0 |
Free cash flow (HKD Mn, OCF less capex) | 389.9 | 72.9 | 416.0 | 381.3 | 691.1 |
Lease principal payments (HKD Mn) | 54.1 | 58.0 | 61.2 | 60.5 | 57.2 |
Dividends paid (HKD Mn) | 186.5 | 77.5 | 99.0 | 160.7 | 189.3 |
Share buybacks (HKD Mn) | 7.9 | 3.6 | 20.2 | 25.1 | 30.5 |
Net investing cash flow (HKD Mn) | -142.7 | -227.9 | -155.0 | -145.5 | -278.1 |
Net financing cash flow (HKD Mn) | -452.1 | -201.8 | -173.6 | -227.7 | -575.7 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE (%, net profit / average total equity) | 15.6 | 9.4 | 16.2 | 15.2 | 20.0 |
ROA (%, net profit / average total assets; FY2021 year-end basis) | 9.9 | 6.1 | 10.7 | 10.1 | 14.0 |
ROIC (%, NOPAT / equity + bank debt + leases − cash) | 14.8 | 9.0 | 15.5 | 15.8 | 19.8 |
Current ratio (x) | 2.09 | 2.39 | 2.83 | 3.02 | 3.24 |
Bank debt / equity (x) | 0.29 | 0.27 | 0.26 | 0.27 | 0.15 |
Net bank debt / EBITDA (x) | 0.06 | 0.39 | -0.03 | -0.11 | -0.31 |
Interest coverage (x, operating income / finance costs) | 21.1 | 12.0 | 13.4 | 11.2 | 23.1 |
Asset turnover (x) | 0.81 | 0.79 | 0.85 | 0.84 | 0.87 |
Days sales outstanding (days) | 65.3 | 73.0 | 67.9 | 66.6 | 68.2 |
Days inventory outstanding (days) | 37.0 | 39.7 | 41.2 | 39.5 | 45.2 |
Days payables outstanding (days) | 20.8 | 19.1 | 19.9 | 15.3 | 18.9 |
Cash conversion cycle (days) | 81.5 | 93.6 | 89.2 | 90.8 | 94.5 |
Revenue by Region
| Region | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Europe revenue (HKD Mn) | 1,254.6 | 1,180.6 | 1,399.4 | 1,618.4 | 1,886.8 |
North America revenue (HKD Mn) | 718.8 | 709.3 | 753.6 | 752.1 | 696.4 |
Greater China revenue (HKD Mn) | 699.2 | 666.7 | 713.6 | 662.2 | 615.4 |
Australia revenue (HKD Mn) | 250.3 | 235.8 | 254.3 | 264.8 | 289.1 |
Others revenue (HKD Mn) | 32.2 | 37.7 | 51.1 | 66.5 | 248.9 |
Revenue by Region (%)
| Region | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Europe share (%) | 42.5 | 41.7 | 44.1 | 48.1 | 50.5 |
North America share (%) | 24.3 | 25.1 | 23.8 | 22.3 | 18.6 |
Greater China share (%) | 23.7 | 23.6 | 22.5 | 19.7 | 16.5 |
Australia share (%) | 8.5 | 8.3 | 8.0 | 7.9 | 7.7 |
Others share (%) | 1.0 | 1.3 | 1.6 | 2.0 | 6.7 |
Region Margins & Growth (%)
| Region | FY2022 | FY2023 | FY2025 |
|---|---|---|---|
Europe, EUR growth (%) | 4.9 | 15.3 | 11.8 |
North America, US$ growth (%) | -1.3 | 6.2 | -7.4 |
Greater China growth (%) | -0.6 | 11.9 | -7.1 |
Australia, AUD growth (%) | 1.1 | 12.8 | 11.8 |
Others growth (%) | 17.0 | 35.6 | 274.1 |
Geographic Revenue
| Region | 1H2025 (HKD Mn) | 1H2026 (HKD Mn) | Original-currency growth (%) | Share 1H2026 (%) |
|---|---|---|---|---|
Europe | 920.3 | 1,093.3 | 10.9 | 53.8 |
North America | 365.7 | 331.3 | -9.4 | 16.3 |
Greater China | 293.2 | 300.0 | Mainland +0.9; HK −8.5 | 14.8 |
Australia | 137.9 | 162.8 | 6.3 | 8.0 |
Others | 117.8 | 145.2 | 23.2 (HK$) | 7.1 |
Share Price History
| Date | Price (HKD) | Source / context |
|---|---|---|
15 Dec 2015 | 4.20 | IPO price |
5-year high (period about 2021) | 11.00 | Market-data 5-year range high |
Sep–Nov 2022 | 1.67–2.08 | Company buyback range (5-year low area of about 1.60) |
May–Dec 2023 | 2.32–3.80 | Company buyback range |
Jan–Jul 2025 | 3.73–4.37 | Company buyback range |
27 Nov 2025 | 5.21 | Close before option grant |
24 Dec 2025 | 5.45 | etnet quote |
29 May 2026 | 5.87 | Press report after Q1 update; market cap HK$5.488bn |
Jun 2026 | 5.79 | Company buyback price |
Undated, about Q3 2026 | 7.62 | Market-data snapshot (YTD about +43%; 52-week range 4.33–8.00) |
Valuation Multiples
| Multiple | At HK$5.87 (29 May 2026) | At HK$7.62 (latest snapshot) |
|---|---|---|
Market cap (HKD Mn) | 5,488 | 7,120 |
EV (HKD Mn; mkt cap − net bank cash + leases + put liabilities + NCI) | ≈5359 | ≈6991 |
P/E TTM (x) | 8.0 | 10.4 |
EV/EBITDA TTM (x) | 5.1 | 6.7 |
EV/Sales TTM (x) | 1.36 | 1.78 |
P/B (x, on equity attributable to owners of HK$3,533.7m) | 1.55 | 2.01 |
Dividend yield TTM (%, 29.0 cents) | 4.9 | 3.8 |
Analyst Ratings & Targets
| Broker / source | Date | Rating | Target (HKD) | Basis |
|---|---|---|---|---|
CGSI (China Galaxy Securities International) | 18 Sep 2025 | Add | 6.88 | 10x FY26F P/E; FY25F net profit HK$545m (actual HK$601m) |
Stockopedia consensus | about mid-2026 | — | 6.88 | Single-broker consensus |
Simply Wall St forecast | Apr 2025 | — | — | Revenue growth about 13% a year over 2 years (now dated) |
Per-Share Data and Returns & Leverage Ratios (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Interim DPS (HK cents) | 7.5 | 3.7 | 6.0 | 8.0 | 10.7 |
Special DPS (HK cents) | 5.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Final DPS (HK cents) | 4.4 | 4.4 | 9.0 | 9.2 | 15.0 |
Total DPS (HK cents) | 16.9 | 8.1 | 15.0 | 17.2 | 25.7 |
Payout ratio (%, DPS / basic EPS) | 44.8 | 35.1 | 35.4 | 39.8 | 40.3 |
Dividends & Capital Returns and Share Count (m)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Buyback spend (HKD Mn) | 7.9 | 3.6 | 20.2 | 25.1 | 30.5 |
Shares repurchased (m) | — | 1.95 | 6.69 | — | 7.33 |
Debt Maturity Profile
| Maturity | 31 Dec 2025 | 30 Jun 2026 |
|---|---|---|
Within 1 year | 70.9 | 78.4 |
Second year | 80.9 | 85.9 |
Third to fifth years | 326.5 | 281.6 |
Total | 478.2 | 445.9 |
Analyst Conclusions
Management guidance.
-
No numeric guidance.
-
The qualitative outlook (1H2026) is:
-
Sustained momentum and further market-share gains from digitalisation.
-
Margin expansion from automation and AI.
-
Selective M&A, especially in aligners.
-
Tariff resilience through China, Vietnam and Thailand production.
-
Continued mid- to long-term optimism on China as VBP standardises pricing.
-
Consensus growth. Thin coverage. The last published broker forecast (CGSI, Sep 2025) was FY2025 net profit of HK$545m, which actual results beat by about 10%. Current FY2026 and FY2027 consensus is n.d.
Run-rate. 1H2026 annualised implies about HK$4.0bn revenue and roughly HK$750m net profit if H2 is seasonally similar (analyst extrapolation, not guidance). For comparison, H2 2025 revenue was HK$1,901.7m and net profit HK$312.6m.
Bull case
-
Structural margin step-up. Gross margin of 58.1% and net margin of 18.6% in 1H2026 were achieved despite an FX headwind, which points to operating leverage from more than 1m digital cases a year rather than currency luck.
-
Underpriced compounder. Net profit grew at about 13.6% CAGR over FY2021–25 and ROIC is about 20% with net cash. Yet the stock trades at about 10x trailing P/E and about 6.7x EV/EBITDA, with a dividend yield of about 4%.
-
Optionality from consolidation. Net bank cash of HK$383m, a proven bolt-on playbook (Hexa Ceram earned HK$24.8m profit in year one) and a fragmented market support accretive roll-ups. The higher-growth adjacencies are aligners (+20%) and sleep devices.
Bear case
-
Geographic decay outside Europe. North America and Greater China fell from 46% of revenue in FY2023 to 31% in 1H2026. Both are shrinking, and the North American onshore asset (MicroDental) earns thin profits against a goodwill-heavy balance sheet.
-
Weak organic volume. Excluding Hexa Ceram, FY2025 volume grew only 2.4%. Margin gains partly reflect cheap RMB labour and favourable EUR crosses that can reverse; FX already swung to a loss in 1H2026.
-
Governance discount is justified. Family control of about 51% plus a combined chair/CEO, option grants without performance conditions to family directors, and a free float of about 32% will cap institutional ownership and the re-rating.
Key catalysts and monitorables (next 12 months)
-
9M2026 operating update (expected about late Nov 2026): organic volume and ASP excluding acquisitions.
-
FY2026 positive profit alert (about mid-Mar 2027) and FY2026 results (about late Mar 2027): whether the gross margin above 58% holds in H2.
-
North America: whether the DSO rationalisation finishes and MicroDental stabilises; tariff policy changes.
-
China: whether the Mainland's positive turn (+0.9% in 1H2026) persists, and whether Hong Kong leakage abates.
-
EUR/RMB and EUR/HK$ cross-rates.
-
M&A announcements, especially aligner-related, and exercise of the Hexa Ceram/Digital Sleep put/call options.
-
Receivables quality: ageing above 3 months and the DSO trend.
-
Grants under the 2026 Share Award and Option schemes, and their dilution.
Analyst verdict. Modern Dental Group has spent five years turning a labour-arbitrage dental-lab network into a digitally routed manufacturing platform, and FY2025–1H2026 is where that work showed up in the numbers.
-
Gross margin moved from 48.9% in FY2022 to 58.1% in 1H2026.
-
Net margin more than doubled.
-
Free cash flow approached HK$700m.
-
The balance sheet moved to net cash on bank debt.
These are institutional-quality metrics. They have been achieved while two of the group's four major regions, North America and Greater China, were contracting. That says something about the strength of the European franchise (50–54% of revenue, growing 11–12% in euros) and about the efficiency of the Dongguan–Thailand–Vietnam production triangle.
The central analytical tension is quality of growth versus quality of margins:
-
Reported revenue growth of about 11% is flattered by acquisitions; organic volume excluding Hexa Ceram grew roughly 2%.
-
FY2025's profit surge had a real FX tailwind.
-
1H2026 matters because the margin expansion continued with FX turning negative. On balance, that supports the view that digital-case economics are structural.
Valuation looks undemanding. At about 10x trailing earnings and under 7x EV/EBITDA, with a roughly 4% yield and about 20% ROIC, the market is applying a heavy discount. The reasons are family control, a combined chair/CEO, thin sell-side coverage and an illiquid free float. That discount is partly deserved and unlikely to close quickly. Even so, it leaves room for returns driven by earnings growth and dividends.
Stance: constructive, with an emphasis on monitoring.
-
The thesis holds while the gross margin stays above about 56%, Europe compounds at high single digits or better in euros, and North America stabilises after the DSO clean-up.
-
The thesis is challenged by a FX-driven margin reversal, rising receivables ageing, or a large, poorly priced acquisition.
Treat price and consensus data as provisional until checked against a live terminal.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure | Background / education | Age | Total remuneration |
|---|---|---|---|---|---|
Dr Chan Ronald Yik Long | Chairman (since 31 Mar 2021), CEO (since 1 Jan 2025), executive director (since 19 Jun 2015) | Joined 2014 | BSc (Biological Sciences), University of Calgary (2008); BDS, HKU (2014); MBA, Heriot-Watt (2015); MSc Aesthetic Restorative Dentistry, Manchester (2019). Registered dentist in Hong Kong; Hon. Clinical Assistant Professor at HKU (since 2022); Hong Kong Young Industrialist Award (2021). Leads Southeast Asia strategy and the clear-aligner business. | 38 (Dec 2024 announcement) | About HK$6.41m (third-party aggregation of the latest annual report); 9.3m options granted Nov 2025 |
Ms Chan Yik Yu | Executive director (since 19 Jun 2015); Chief Marketing Officer | Joined 2014 | University of Calgary graduate (2010); vice-chairman and deputy GM of a subsidiary; director of Triera Holdings | 38 | About HK$3.76m; 9.3m options |
Mr Chan Kwun Pan | Executive director | Group founder generation | Father of Dr Chan Ronald and Ms Chan Yik Yu | About 68 | About HK$3.74m; 0.93m options |
Mr Chan Chi Yuen | Executive director | — | Cousin of Dr Chan Ronald | About 41 | About HK$3.75m; 0.93m options |
Mr Chan Kwun Fung | Non-executive director (re-designated from executive, about Apr 2025) | Joined Nov 1991; director since Jul 2012 | Controlling-family patriarch; director of Triera Holdings | 70 (Mar 2025) | About HK$3.74m; 0.93m options |
Dr Cheung Wai Bun Charles, J.P. | INED; Audit Committee chair | Since Dec 2015 | — | — | About HK$0.36m |
Dr Chan Yue Kwong Michael | INED; Nomination Committee chair | Since Dec 2015 | — | — | About HK$0.36m |
Dr Yau Ka Po | INED; Remuneration Committee chair (from 15 Dec 2025) | About 4 years | — | — | About HK$0.36m |
Executive Leadership Team
| Name | Title | Notes |
|---|---|---|
Mr Kwan Ngai Kit | CFO and Company Secretary | Since 25 Oct 2016; about 46 |
Mr August Wilhelm Torsten Schwafert | CEO, Modern Dental Europe BV | Per market-data profiles; current status n.d. |
Mr Gregory Scialom | President, Labocast SAS | Per market-data profiles |
Mr James Squirrell | CEO, Modern Dental Pacific Pty Ltd | Per market-data profiles |
Mr Kwan Chi Hang Thomas | Employee (option grantee) | Spouse of Ms Chan Yik Yu; received 0.93m options |
Richie Leung | Business Director, Modern Dental South East Asia | Per 2024 trade interview |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
1 Jul 2022 | Ngai Chi Ho Alwin resigns as Vice-Chairman, executive director and COO | Personal reasons (leaving Greater China) |
31 Dec 2024 / 1 Jan 2025 | CEO Ngai Shing Kin retires; Dr Chan Ronald appointed CEO | Generational transfer to the Chan family's second generation; chair/CEO combined |
About Apr 2025 | Chan Kwun Fung re-designated as non-executive director | Founder steps back from executive duties |
15 Dec 2025 | Dr Cheung Wai Man William retires as INED | To focus on FDI World Dental Federation commitments; no disagreement |
26 Mar / 28 May 2026 | 2026 Share Award Scheme adopted; 2026 Share Option Scheme adopted at AGM | Replaces the expired 2015 option scheme and 2015 RSU scheme |
Major Shareholders
| Holder | Shares (m) | Stake (%) | Date |
|---|---|---|---|
Chan Kwun Fung & family (incl. Triera Holdings) | 474.39 | 50.74 | 15 Aug 2025 |
Ngai Shing Kin (former CEO) | 98.04 | 10.49 | 15 Aug 2025 |
Ngai Chi Ho Alwin (former COO) | 63.12 | 6.75 | 15 Aug 2025 |
Top-10 institutional holders | — | — | Not in sources reviewed |
Competitive Landscape
Key Competitors
| Competitor | Type | Overlap with MDG | Revenue / scale | Relative positioning |
|---|---|---|---|---|
Glidewell Laboratories (US) | Private lab and materials group | Fixed and removable prosthetics in the US | n.d. (private) | Largest US lab; vertically integrated into materials and milling; competes with MicroDental |
National Dentex Labs / NDX (US) | Private lab network | US fixed and removable; DSO accounts | n.d. (private) | Consolidator rival in North America |
Flemming Dental (Germany) | Private lab network | German fixed and removable | — | Domestic rival to Permadental |
Protilab (France) | Offshore-production lab | French offshore crowns and bridges | — | Direct price competitor to Labocast |
Small independent labs (Europe, US, Australia, China) | Thousands of micro-labs | All segments | — | MDG's main share donor as digitisation consolidates the market |
Mainland China domestic labs (various) | Private | China fixed and implant prosthetics under VBP | — | Drove "prolonged intense price competition" in FY2024–25 |
Align Technology (US) | Listed OEM | Clear aligners vs TrioClear; iTero scanners | FY2024 revenue about US$4.0bn | Category leader; TrioClear is a niche follower |
Angelalign Technology (HK: 6699) | Listed aligner OEM | Aligners in China and Asia | — | Aligner competitor in Asia |
Dentsply Sirona (US) | Listed OEM | Chairside CAD/CAM (CEREC) substitutes lab crowns; aligners (SureSmile) | FY2024 revenue about US$3.8bn | Chairside milling is a disintermediation threat |
Straumann Group (CH) | Listed OEM | Implant components, aligners (ClearCorrect), digital workflows | FY2024 revenue about CHF 2.5bn | Supplier and partial competitor |
Envista (US) | Listed OEM | Spark aligners; scanners (Nobel/Ormco) | FY2024 revenue about US$2.5bn | Adjacent |
Peer Comparison FY2025
| Metric | Modern Dental (FY2025) | Align Technology (FY2024) | Dentsply Sirona (FY2024) | Straumann (FY2024) |
|---|---|---|---|---|
Revenue | HK$3,737m (≈US$480m) | ≈US$4.0bn | ≈US$3.8bn | ≈CHF 2.5bn |
Revenue growth | +11.1% | n.d. here | n.d. here | n.d. here |
Gross margin | 55.8% | n.d. here | n.d. here | n.d. here |
EBITDA margin | 25.1% | n.d. here | n.d. here | n.d. here |
R&D % of revenue | 1.0% | n.d. here | n.d. here | n.d. here |
Recent Developments
Headcount rose to 8,575.



